Revue medicale suisse
August 23, 2023
G. Thorens, Louise Penzenstadler, F. Seragnoli et al.
2 citations
The article proposes ten essential ethical points for the practice of psychedelic-assisted psychotherapy (PAP): respecting legal frameworks for psychotropic drugs, managing psychedelics safely (storage, production, security), reporting adverse effects to authorities, guaranteeing psychotherapeutic follow-up, ensuring patient safety during treatment, basing indications on scientific evidence, separating personal recreational use from medical use, avoiding proselytizing or poor medical practices, not equating personal psychedelic consumption with clinical competence, and ensuring equitable and reasonable access to care.
Revue medicale suisse
April 23, 2025
Louise Penzenstadler, Sandra Baudois, Alma Lingenberg et al.
Psychedelics like psilocybin and LSD, acting through 5-HT2A receptors, rapidly and lastingly improve depression and anxiety by modulating neuroplasticity and brain connectivity. They may also help with addictions, post-traumatic stress, and obsessive-compulsive disorder. This article explores their potential in Parkinson's disease, both for treating depression, anxiety, and impulse control disorders and for neuroprotection. Psychedelics stimulate synaptogenesis, increase brain-derived neurotrophic factor, and have anti-inflammatory effects. However, clinical trials are needed to confirm safety and efficacy in Parkinson's disease.
Revue medicale suisse
February 12, 2025
Marco Solcà, Lola De Marcos Fuentes, Marie My Lien Rebetez et al.
Eating disorders involve a transformation of the essential act of eating from a source of pleasure and relational bonding into a source of psychological distress with somatic consequences and impacts on individual and environmental functioning. Recent advances in diagnostic and etiopathogenic approaches have improved understanding of these disorders. Innovative techniques including neuromodulation, virtual reality, and psychedelics are opening possibilities for more targeted and individualized therapies.
Revue medicale suisse
April 3, 2024
Marion Waeber, Guglielmo Maria Pozzetti, Nicolas Donzé
Entheogens are little-known psychoactive substances whose use is frequently encountered in outpatient care and can cause harm. This article examines five such substances rarely described in medical literature. Few studies exist on their long-term health effects, and authorities do not view this niche consumption as problematic. Rapid screening is unavailable, and overdose management is often limited to non-specific supportive care with benzodiazepines.
Revue medicale suisse
February 14, 2024
Aude Molinard-Chenu, Georgios Tsimploulis, Louise Penzenstadler et al.
Psychedelics are being investigated as a new therapeutic approach for chronic pain. They can influence the serotonergic system, which affects central pain sensitization. Ketamine, already used for chronic pain, can reduce pain, but more studies are needed on its long-term effectiveness. Classic psychedelics are also drawing interest for their potential analgesic, anti-inflammatory, and functional effects, though research is limited. These findings encourage further investigation.
Revue medicale suisse
December 20, 2023
Amandine Schaller, Géraldine Bourquin, Indira Amorim Araujo et al.
Psychedelic-assisted psychotherapy (PAP) combines preparation, substance intake, and integration of experiences to facilitate profound psychospiritual change. Despite methodological and administrative hurdles, interest in this innovative approach continues to grow because of its potential to offer remission where conventional approaches have shown little benefits.
Revue medicale suisse
June 21, 2023
Jelena Stanic, David Jackson-Perry, Corine Courvoisier et al.
Mindfulness meditation programs can help people cope with psychological or physical symptoms such as pain, but they remain uncommon in French-speaking somatic clinical settings despite scientific validation. This article describes three mindfulness meditation programs offered at Lausanne University Hospital to people living with HIV, cancer, or chronic pain, and discusses challenges related to participant involvement and program implementation in a Swiss teaching hospital.